SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 3,318 Shares

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 3,318 shares of SiBone stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $12.87, for a total transaction of $42,702.66. Following the completion of the transaction, the chief financial officer owned 263,148 shares of the company’s stock, valued at $3,386,714.76. The trade was a 1.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, February 17th, Anshul Maheshwari sold 21,528 shares of SiBone stock. The shares were sold at an average price of $15.37, for a total transaction of $330,885.36.

SiBone Stock Performance

Shares of SIBN stock remained flat at $13.12 during trading on Friday. 673,231 shares of the company were exchanged, compared to its average volume of 599,931. The stock has a 50-day moving average price of $14.69 and a 200-day moving average price of $16.39. The company has a market capitalization of $579.51 million, a P/E ratio of -29.82 and a beta of 0.77. SiBone has a 12 month low of $12.15 and a 12 month high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.55 and a quick ratio of 7.21.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. The business had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. As a group, sell-side analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd purchased a new stake in shares of SiBone in the fourth quarter worth $29,000. Royal Bank of Canada boosted its stake in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after buying an additional 736 shares during the period. Caitong International Asset Management Co. Ltd grew its position in SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after buying an additional 1,941 shares in the last quarter. State of Alaska Department of Revenue bought a new position in SiBone in the 3rd quarter worth about $39,000. Finally, Kemnay Advisory Services Inc. bought a new position in SiBone in the 4th quarter worth about $53,000. Institutional investors own 98.11% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Canaccord Genuity Group raised their target price on SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC lifted their target price on SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. TD Cowen upped their price target on SiBone from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Finally, Truist Financial reissued a “buy” rating and issued a $24.00 price target (up from $23.00) on shares of SiBone in a report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.67.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.